A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical
The emergence of cell-cultured protein has sparked intense debate at the intersection of agricultural tradition and technological innovation, nowhere more so than in states with deep roots in the livestock industry. In South Dakota, a legislative effort to completely prohibit the sale of lab-grown
Today, we sit down with Ivan Kairatov, a biopharma expert whose career has been dedicated to the intersection of technology, research, and development. As artificial intelligence begins to unlock the very code of life, it presents a dual-use dilemma of unprecedented scale—promising revolutionary
In a move that sends ripples across the global pharmaceutical landscape, AstraZeneca has committed to a landmark $15 billion investment in China, a strategic initiative designed to run through 2030. The announcement, made on January 29, 2026, signals a profound deepening of the company's research,
For decades, respiratory syncytial virus (RSV) was largely perceived as a threat to infants and the elderly. However, a seismic shift is underway, challenging this long-held view and repositioning RSV as a significant public health concern for a much broader adult population. Recent regulatory
The once-unbreakable bond between the United States and the World Health Organization has officially been severed, sending shockwaves through the global public health infrastructure and raising urgent questions about the future of international cooperation in an era of resurgent nationalism. This
